Zuellig Pharma
Concise Prescribing Info
Idiopathic gout, uric acid lithiasis, acute uric acid nephropathy; neoplastic & myeloproliferative disease w/ high cell turnover rates in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders ie, hypoxanthine guanine phosphoribosyltransferase eg, Lesch-Nyhan syndrome; glucose-6-phosphatase eg, glycogen storage disease; phosphoribosylpyrophosphate synthetase & amidotransferase; adenine phosphoribosyltransferase. Management of 2, 8-dihydroxyadenine renal stones related to deficient activity of adenine phosphoribosyltransferase & recurrent mixed Ca oxalate renal stones in the presence of hyperuricosuria.
Dosage/Direction for Use
Adult Mild conditions 2-10 mg/kg daily or 100-200 mg daily. Moderately severe conditions 300-600 mg daily. Severe conditions 700-900 mg daily. Childn <15 yr 10-20 mg/kg daily or up to max: 400 mg daily.
Should be taken with food: Take immediately after meals.
Special Precautions
Discontinue use if hypersensitivity reactions occur. HTN or cardiac insufficiency. Not for asymptomatic hyperuricaemia. Not to be started until acute gout has completely subsided. Conditions w/ increased urate formation eg, malignant disease, Lesch-Nyhan syndrome. Impaction of uric acid renal stones. HLA-B*5801 allele carrier. Increased TSH values on long-term use. Ensure adequate hydration. Not to be taken by patients w/ intolerance, Lapp lactose deficiency or glucose-galactose malabsorption. Concomitant use w/ diuretics. May affect ability to drive & use machines. Renal or hepatic impairment. Pregnancy.
Drug Interactions
Increased plasma t½ of vidarabine. Decreased effect by uricosurics eg, probenecid & large doses of salicylates. Increased risk of prolonged hypoglycaemic activity w/ chlorpropamide. Increased effect of warfarin, other coumarin anticoagulants. Inhibited hepatic oxidation of phenytoin. Inhibited metabolism of theophylline. Increased frequency of skin rash w/ ampicillin or amoxicillin. Enhanced bone marrow suppression by cyclophosphamide. Increased plasma conc of cyclosporin, oxipurinol, serum urate. Doubled plasma Cmax & AUC of didanosine. Increased risk of hypersensitivity w/ diuretics, ACE inhibitors. Concurrent use w/ 6-mercaptopurine or azathioprine.
MIMS Class
Hyperuricemia & Gout Preparations
ATC Classification
M04AA01 - allopurinol ; Belongs to the class of preparations inhibiting uric acid production. Used in the treatment of gout.
Zyloric tab 100 mg
100's (RM89.35/pack)
Zyloric tab 300 mg
30's (RM71.4/pack)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in